RPS29P22

Across TCGA pan-cancer cohorts, RPS29P22 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated RPS29P22 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPS29P22 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPS29P22 expression acts as an unfavorable survival marker, although some lineages such as BLCA and READ show a favorable association.

STAD, CHOL, and BLCA are the cancer types where RPS29P22 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	II,III,IV	0.357	0.642	<.001	61	view →
CHOL	OS	Tertile	III,IV	0.162	0.915	.004	45	view →
BLCA	DFS	Tertile	III,IV	0.602	0.409	.002	36	view →
READ	OS	Tertile	III,IV	0.892	0.393	.017	22	view →
ACC	OS	Tertile	III,IV	0.241	0.613	.011	18	view →
TGCT	DFS	Tertile	III,IV	0.604	1.000	.044	18	view →
MESO	OS	Quartile	IV	0.309	0.650	.036	15	view →
KIRP	DFS	Tertile	All	1.000	0.681	.028	12	view →
GBM	OS	Tertile	All	0.261	0.435	.036	9	view →
LUSC	DFS	Tertile	All	0.911	0.743	.029	9	view →
LIHC	DFS	Tertile	II,III,IV	0.146	0.468	.033	9	view →
DLBC	DFS	Tertile	All	0.858	0.406	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

RPS29P22–STAD (DFS)

Open the STAD breakdown →